ReviewEndocrine reviews2013
Evolving approaches to patients with advanced differentiated thyroid cancer.
Review in Endocrine reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.
- Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2015Guideline
- Lomibuvir sensitizes radioiodine-resistant thyroid cancer cell lines to radioiodine treatment by targeting hTERT RNA-dependent polymerase activity.Journal of endocrinological investigation · 2025Article
- Correlation between gene mutations and clinical characteristics in papillary thyroid cancer: a retrospective analysis of BRAF mutations and RET rearrangements.Thyroid research · 2024Article
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal transduction and targeted therapy · 2024Review
- Fusion Oncogenes in Patients With Locally Advanced or Distant Metastatic Differentiated Thyroid Cancer.The Journal of clinical endocrinology and metabolism · 2024Article
- Article
- Identification of m6A-associated LncRNAs as predict factors for the immune infiltration and prognosis of thyroid cancer.Annals of medicine · 2023Article
- Association of BRAF V600E Mutation with Tumor Recurrence in a Small Sample of Filipino Patients with Papillary Thyroid Cancer in a Single Center.Acta medica Philippina · 2023Article
- Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response.Frontiers in endocrinology · 2023Review
- Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive-resistant differentiated thyroid cancer.Cancer medicine · 2022Review
- Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study.European thyroid journal · 2022Article
- The Specifically Androgen-Regulated Gene (SARG) Promotes Papillary Thyroid Carcinoma (PTC) Lymphatic Metastasis Through Vascular Endothelial Growth Factor C (VEGF-C) and VEGF Receptor 3 (VEGFR-3) Axis.Frontiers in oncology · 2022Article
- Expression of epithelial membrane protein (EMP) 1, EMP 2, and EMP 3 in thyroid cancer.Histology and histopathology · 2022Article
- miR-30b-5p inhibits proliferation, invasion, and migration of papillary thyroid cancer by targeting GALNT7 via the EGFR/PI3K/AKT pathway.Cancer cell international · 2021Article
- Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma - A Real-World Experience.Cancer management and research · 2021Article
- XBP1s Acts as a Tumor Suppressor to Inhibit the EMT Process and Metastasis of Papillary Thyroid Cancer.OncoTargets and therapy · 2021Article
- Metabolic programming of tumor associated macrophages in the context of cancer treatment.Annals of translational medicine · 2020Review
- The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study.European journal of histochemistry : EJH · 2020Article
- LncRNA NBR2 Inhibits the Malignancy of Thyroid Cancer, Associated With Enhancing the AMPK Signaling.Frontiers in oncology · 2020Article
- Microfluidic Droplet Digital PCR Is a Powerful Tool for Detection of BRAF and TERT Mutations in Papillary Thyroid Carcinomas.Cancers · 2019Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Advanced differentiated thyroid cancer (DTC), defined by clinical characteristics including gross extrathyroidal invasion, distant metastases, radioiodine (RAI) resistance, and avidity for 18-fluorodeoxyglucose (positron emission tomography-positive), is found in approximately 10-20% of patients with DTC. Standard therapy (surgery, RAI, TSH suppression with levothyroxine) is ineffective for many of these patients, as is standard chemotherapy. Our understanding of the molecular mechanisms leading to DTC and the transformation to advanced DTC has rapidly evolved over the past 15-20 years. Newer targeted therapy, specifically inhibitors of intracellular kinase signaling pathways, and cooperative multicenter clinical trials have dramatically changed the therapeutic landscape for patients with advanced DTC. In this review focusing on morbidities, molecules, and medicinals, we present a patient with advanced DTC, explore the genetics and molecular biology of advanced DTC, and review evolving therapies for these patients including multikinase inhibitors, selective kinase inhibitors, and combination therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.